Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 1:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 17,842 matching trials from the live ClinicalTrials.gov search.
Conditions
Central Nervous System Neoplasms, Medulloblastoma
Interventions
Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more
Conditions
Dengue
Interventions
Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Covid19
Interventions
TQ Formula/Tab
Drug
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

3BNC117-LS First-in-Human Phase 1 Study

NCT03254277
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117-LS, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Painful Diabetic Neuropathy
Interventions
Oral dose CNTX-6016 or oral dose Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
60
States / cities
Gilbert, Arizona • Phoenix, Arizona • Encino, California + 56 more
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
Interventions
19(T2)28z1xx CAR T cells
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Autistic Disorder
Interventions
Aripiprazole, Placebo, D-cycloserine
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
ADCT-301
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
11
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

NCT05164471
Conditions
Hemophilia B
Interventions
verbrinacogene setparvovec
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
Conditions
Pancreatic Ductal Adenocarcinoma, Sarcoma
Interventions
Decitabine, Gemcitabine
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, sorafenib tosylate, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Interventions
Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI)
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Years to 90 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematologic and Lymphocytic Disorder, Hematopoietic Cell Transplantation Recipient, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis, T-Cell Non-Hodgkin Lymphoma, Thrombocytopenia, Venous Thromboembolism
Interventions
Platelet Transfusion
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Geographic Atrophy
Interventions
APL-2, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
67
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
Completed Phase 1 Interventional Results available

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

NCT03997760
Conditions
Sickle Cell Disease
Interventions
TAK-755, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
Conditions
Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 59 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
Xywav, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
27
States / cities
Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 23 more
Conditions
Head and Neck Cancer
Interventions
RAD001, Cetuximab, Cisplatin, Carboplatin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Endometriosis
Interventions
OG-6219, Placebo
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more